Amgen Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Amgen reports 58 percent lower death risk in trial for Amgen stock

Clinical trial results Drug approval AI-generated analysis

πŸ“ˆ Amgen reported a 58 percent lower risk of death in the DeLLphi-305 Phase 3 trial for an Imdelltra and Imfinzi combination in extensive-stage small cell lung cancer.

⏱️ Median overall survival reached 21.10 months with the combination versus 12.70 months with Imfinzi alone, while progression-free survival improved to 7.40 months from 1.90 months.

πŸ‘₯ Nearly 80 percent of patients in the combination group were alive after one year compared to 53 percent for those receiving Imfinzi alone.

⚠️ The combination therapy resulted in a higher incidence of Grade 3 or higher treatment-related adverse events at 20.90 percent versus 10.80 percent for Imfinzi monotherapy.

πŸ’° Amgen's second-quarter oncology portfolio generated approximately USD 2 billion, with Imdelltra sales rising 115 percent year over year to USD 288 million.

πŸ“ˆ The company raised its full-year 2026 revenue outlook to a range of USD 38.2 billion to USD 39.4 billion following the strong second-quarter performance.

🏒 Amgen reported second-quarter adjusted earnings per share of USD 6.29 on total revenue of USD 10.05 billion.

πŸ“‰ The stock traded at EUR 395.63 with a market capitalization of USD 237.5 billion as of October 23, 2026.

Bullish Signals
  • Amgen demonstrated a 58 percent lower risk of death in the DeLLphi-305 Phase 3 trial for its Imdelltra and Imfinzi combination therapy.
  • Median overall survival in the trial reached 21.10 months with the combination versus 12.70 months with Imfinzi alone, indicating a significant efficacy boost.
  • Nearly 80 percent of patients in the combination group survived past one year compared to 53 percent for the monotherapy group.
  • Amgen raised its full-year 2026 revenue outlook to USD 38.2 billion-USD 39.4 billion following a strong second quarter.
  • The company achieved second-quarter revenue of USD 10.05 billion and adjusted earnings per share of USD 6.29.
Risk Factors
  • The Imdelltra and Imfinzi combination therapy was associated with a higher rate of Grade 3 or higher treatment-related adverse events at 20.90 percent compared to 10.80 percent for Imfinzi alone.
  • Regulatory review and commercial execution remain critical next steps required before the new indication can materially reshape the company's growth.
Full Analysis
Amgen announced positive Phase 3 trial data for its Imdelltra and Imfinzi combination therapy in extensive-stage small cell lung cancer on October 24, 2026. The DeLLphi-305 study demonstrated a 58 percent lower risk of death compared to Imfinzi alone, with median overall survival reaching 21.10 months versus 12.70 months for the monotherapy. The clinical results showed that nearly 80 percent of patients in the combination group remained alive after one year, compared to 53 percent with Imfinzi alone. Progression-free survival was also significantly improved at 7.40 months versus 1.90 months. However, the combination therapy did carry a higher rate of Grade 3 or higher adverse events (20.90 percent) compared to the monotherapy (10.80 percent). This data provides a fresh clinical reference point for Amgen's oncology pipeline, which generated approximately USD 2 billion in revenue during the second quarter. While Imdelltra sales have already risen 115 percent year over year to USD 288 million, the company faces the next tests of regulatory review and commercial execution to determine if this new indication can materially reshape its growth trajectory. Amgen raised its full-year 2026 revenue outlook to between USD 38.2 billion and USD 39.4 billion following strong second-quarter earnings of USD 10.05 billion. The stock, trading around EUR 395.63 with a market cap of USD 237.5 billion, now has a concrete pipeline variable ahead of its next reported results.